Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.
Zafar I. Malik
Honoraria - Astellas Pharma; AstraZeneca; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi
Giuseppe Di Lorenzo
No relevant relationships to disclose
Mert Basaran
No relevant relationships to disclose
Alexandros Ardavanis
Employment or Leadership Position - 1st Dpt of Medical Oncology Saint Savas Hospital, Athens, Greece
Honoraria - Novartis; Sanofi
Phillip Parente
Consultant or Advisory Role - Sanofi
Wito de Schultz
No relevant relationships to disclose
Fred Saad
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Inge van Oort
Honoraria - Sanofi
Winald R. Gerritsen
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Luis M. Antón Aparicio
Employment or Leadership Position - Complejo Hospitalario Universitario de A Coruña
Geoffrey Matus
No relevant relationships to disclose
Simon Hitier
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Axel Heidenreich
Consultant or Advisory Role - Amgen; Astellas Pharma; Janssen; Pfizer; Sanofi ; Takeda
Honoraria - Astellas Pharma; Bayer; Ipsen; Janssen; Sanofi ; Takeda
Research Funding - Astellas Pharma; Sanofi
Amit Bahl
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi